Nkarta (NKTX) Operating Income (2019 - 2026)
Nkarta (NKTX) posted quarterly Operating Income of -$30.9 million for Q1 2026, up 15.56% year-over-year from -$26.7 million in Q1 2025, and little changed quarter-over-quarter from -$31.0 million in Q4 2025.
Nkarta (NKTX) Operating Income (2019 - 2026) Analysis & Trends
Nkarta's Operating Income history runs 8 years deep, the most recent figure standing at -$30.9 million for Q1 2026.
- In Q1 2026, Operating Income rose 15.56% year-over-year to -$30.9 million; the TTM figure through Mar 2026 stood at -$116.3 million (up 11.88% YoY), while the FY2025 annual figure was -$122.0 million, up 4.83% from the prior year.
- Operating Income for Q1 2026 stood at -$30.9 million, roughly flat from -$31.0 million in the prior quarter.
- The five-year high for Operating Income was -$26.1 million in Q1 2022, with the low at -$36.9 million in Q2 2023.
- The 5-year median for Operating Income is -$30.9 million (2024), against an average of -$31.3 million.
- The sharpest annual moves came in 2022 and 2025: Operating Income plunged 52.85% in 2022, then advanced 19.26% in 2025.
- Nkarta's Operating Income stood at -$35.0 million in 2022, then advanced by 10.86% to -$31.2 million in 2023, then rose by 0.84% to -$30.9 million in 2024, then dropped by 0.12% to -$31.0 million in 2025, then advanced by 0.27% to -$30.9 million in 2026.
- Business Quant data shows NKTX's Operating Income at -$30.9 million in Q1 2026, -$31.0 million in Q4 2025, and -$27.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | -43.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.13 Mn |
| Mar 31, 2026 | -30.88 Mn |
| Dec 31, 2025 | -30.96 Mn |
| Sep 30, 2025 | -27.29 Mn |
| Jun 30, 2025 | -27.19 Mn |
| Mar 31, 2025 | -36.56 Mn |
| Dec 31, 2024 | -30.92 Mn |
| Sep 30, 2024 | -33.79 Mn |
| Jun 30, 2024 | -30.72 Mn |
| Mar 31, 2024 | -32.76 Mn |
| Dec 31, 2023 | -31.19 Mn |
| Sep 30, 2023 | -29.29 Mn |
| Jun 30, 2023 | -36.86 Mn |
| Mar 31, 2023 | -34.31 Mn |
| Dec 31, 2022 | -34.98 Mn |
| Sep 30, 2022 | -30.26 Mn |
| Jun 30, 2022 | -27.61 Mn |
| Mar 31, 2022 | -26.10 Mn |
| Dec 31, 2021 | -22.89 Mn |
| Sep 30, 2021 | -22.43 Mn |